Inhibrx Biosciences, Inc. (INBX)
USD 14.09
(-3.16%)
USD 14.09
(-3.16%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.8 Million | 2.17 Million | 7.12 Million | 12.8 Million | 9.09 Million | 7.5 Million |
| Cost of Revenue | 1.19 Million | 2.84 Million | 2.68 Million | 73.49 Million | 47.9 Million | 33.45 Million |
| Gross Profit | 609 Thousand | -668 Thousand | 4.43 Million | -60.68 Million | -38.81 Million | -25.95 Million |
| Operating Expenses | 219.83 Million | 131.29 Million | 83.68 Million | 80.25 Million | 52.8 Million | 37.01 Million |
| Selling, General and Administrative Expenses | 29.38 Million | 21.12 Million | 12.35 Million | 6.83 Million | 9.01 Million | 4.65 Million |
| Research and Development Expenses | 191.64 Million | 110.18 Million | 71.44 Million | 73.49 Million | 47.9 Million | 33.45 Million |
| Other Expenses | - | -14 Thousand | -106 Thousand | -80 Thousand | -4.11 Million | 68 Thousand |
| Cost and Expenses | 221.02 Million | 131.29 Million | 83.68 Million | 80.25 Million | 52.8 Million | 37.01 Million |
| Operating Income | -219.22 Million | -129.11 Million | -76.56 Million | -67.44 Million | -43.71 Million | -29.51 Million |
| Interest Expense | 31.84 Million | 16.1 Million | 5.21 Million | 10.81 Million | 5.71 Million | 1.48 Million |
| Income Tax Expense | 3000.00 | 3000.00 | 2000.00 | 3000.00 | 898 Thousand | 96 Thousand |
| Earnings before Tax | -239.72 Million | -145.22 Million | -81.76 Million | -75.63 Million | -50.5 Million | -30.92 Million |
| Net Income | -241.36 Million | -145.22 Million | -81.76 Million | -75.63 Million | -51.4 Million | -31.16 Million |
| Earnings Per Share Basic | -5.12 | -3.62 | -2.15 | -2.99 | -1.41 | -1.15 |
| Earnings Per Share Diluted | -5.12 | -3.62 | -2.15 | -2.99 | -1.41 | -1.15 |
| Weighted Average Shares Outstanding | 47.13 Million | 40.1 Million | 38.01 Million | 25.26 Million | 36.55 Million | 27.07 Million |
| Weighted Average Shares Outstanding (Diluted) | 47.13 Million | 40.1 Million | 38.01 Million | 25.26 Million | 36.55 Million | 27.07 Million |
| Gross Margin | 0.34 | -0.31 | 0.62 | -4.74 | -4.27 | -3.46 |
| EBIT Margin | -114.83 | -59.28 | -10.75 | -5.27 | -4.69 | -3.84 |
| Profit Margin | -134.09 | -66.68 | -11.48 | -5.91 | -5.65 | -4.16 |
| EBITDA | -206.69 Million | -125.81 Million | -76.56 Million | -67.44 Million | -42.6 Million | -28.76 Million |
| Earnings Before Tax Margin | -121.79 | -59.28 | -10.75 | -5.27 | -4.81 | -3.94 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 100 Thousand | - | 1.63 Million | 1.8 Million | 119 Thousand | 30 Thousand |
| Cost of Revenue | 475 Thousand | 360 Thousand | 298 Thousand | 1.19 Million | 304 Thousand | 731 Thousand |
| Gross Profit | -375 Thousand | -360 Thousand | 1.33 Million | 609 Thousand | -185 Thousand | -701 Thousand |
| Operating Expenses | 160.52 Million | 73.46 Million | 89.62 Million | 219.83 Million | 45.94 Million | 41.36 Million |
| Selling, General and Administrative Expenses | 93.26 Million | 9.87 Million | 7.78 Million | - | 7.88 Million | 7.26 Million |
| Research and Development Expenses | 67.25 Million | 63.59 Million | 81.83 Million | - | 38.05 Million | 34.1 Million |
| Other Expenses | 33 Thousand | -59 Thousand | -158 Thousand | -580 Thousand | -5.96 Million | -217 Thousand |
| Cost and Expenses | 160.99 Million | 73.82 Million | 89.92 Million | 221.02 Million | 45.94 Million | 41.36 Million |
| Operating Income | -160.89 Million | -73.82 Million | -88.28 Million | -219.22 Million | -45.82 Million | -41.33 Million |
| Interest Expense | 5.36 Million | 8.13 Million | 8.22 Million | 31.84 Million | 8.14 Million | 7.9 Million |
| Income Tax Expense | 2000.00 | 316.72 Thousand | -4000.00 | 3000.00 | 2000.00 | 5000.00 |
| Earnings before Tax | 1.85 Billion | -78.71 Million | -91.97 Million | -239.72 Million | -51.78 Million | -47.04 Million |
| Net Income | 1.85 Billion | -78.71 Million | -93.6 Million | -241.36 Million | -51.78 Million | -47.05 Million |
| Earnings Per Share Basic | 128.35 | -1.44 | -1.73 | - | -1.10 | -1.08 |
| Earnings Per Share Diluted | 128.35 | -1.44 | -1.73 | - | -1.10 | -1.08 |
| Weighted Average Shares Outstanding | 14.47 Million | 54.55 Million | 54.03 Million | 47.13 Million | 47.15 Million | 43.64 Million |
| Weighted Average Shares Outstanding (Diluted) | 14.47 Million | 54.55 Million | 54.03 Million | 47.13 Million | 47.15 Million | 43.64 Million |
| Gross Margin | -3.75 | - | 0.82 | 0.34 | -1.55 | -23.37 |
| EBIT Margin | -1604.23 | - | -53.85 | - | -385.10 | -1294.93 |
| Profit Margin | 18.58 Thousand | - | -57.29 | -134.09 | -435.20 | -1568.40 |
| EBITDA | -160.42 Million | -73.46 Million | -87.99 Million | - | -45.82 Million | -38.84 Million |
| Earnings Before Tax Margin | -1608.98 | - | -54.03 | -121.79 | -385.10 | -1377.97 |
CSKL
LLOYDSENGG
281740
MMTC
002890
ANX